An Exploratory Study of Sunitinib in Combination with Docetaxel and Trastuzumab as First-Line Therapy for Her2-Positive Metastatic Breast Cancer
AuthID
P-002-2Q4
P-002-2Q4
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service